BACKGROUND: Recurrence and toxicity occur commonly among patients with rectal cancer who are treated with 5-fluorouracil (5-FU). The authors hypothesized that genetic variation in folate-metabolizing genes could play a role in interindividual variability. The objective of the current study was to evaluate the associations between genetic variants in folate-metabolizing genes and clinical outcomes among patients with rectal cancer treated with 5-FU. METHODS: The authors investigated 8 functionally significant polymorphisms in 6 genes (methylenetetrahydrofolate reductase [MTHFR] 
INTRODUCTION
Colorectal cancer is a major cause of cancer-related death. Among patients with stages II and III rectal cancer, 5-fluorouracil (5-FU)-based chemotherapy regimens with radiotherapy (XRT) before and=or after surgery are the standard care. 1, 2 The major mechanism of action of 5-FU is the inhibition of thymidylate synthase (TS) through an active metabolite, which forms a complex with TS and 5,10 methylenetetrahydrofolate (5,10-MTHF). 3, 4 Intracellular MTHF levels are controlled by methylenetetrahydrofolate reductase (MTHFR), a key enzyme in folate-related one-carbon metabolism (FOCM). 3, 4 The solute carrier family 19 member 1, encoded by the SLC19A1 gene, and dihydrofolate reductase (DHFR) also play essential roles in the FOCM pathway by providing tetrahydrofolate and MTHF for the cells. [5] [6] [7] There are large interindividual differences in the therapeutic response to 5-FU and the attendant toxicities. 2 Polymorphisms in genes involved in FOCM could explain some of the interindividual differences in clinical response and toxicity to 5-FU. 8, 9 Two common single-nucleotide polymorphisms (SNPs) in the MTHFR gene (C677T and A1298C) confer decreased MTHFR enzyme activity 10, 11 and alter intracellular folate intermediates. 12 Some studies have reported associations between MTHFR gene polymorphisms and clinical outcome in patients with colorectal cancer, [13] [14] [15] [16] [17] [18] [19] whereas others have not. [20] [21] [22] [23] [24] [25] [26] [27] However, to our knowledge, very little is known regarding the associations between polymorphisms in the MTHFR gene, other FOCM genes, and clinical outcomes in patients with rectal cancer. Because clinical response to 5-FU and toxicity differ substantially among patients with rectal cancer, 2 the identification of predictive markers of clinical outcome and chemotherapy-related toxicity is needed to deliver targeted therapies. 8 To address these gaps in knowledge, we performed a comprehensive analysis of the associations between functional significant polymorphisms in MTHFR (C677T and A1298C), SLC19A1 (G80A), SHMT1 (C1420T), DHFR (IVS1 del19bp), TS 1494del, and TSER and clinical outcomes (overall survival [OS] , disease-free survival [DFS] , and toxicity) in patients with TNM stage II or III rectal cancer enrolled in a phase 3 adjuvant clinical trial (GI INT-0144; Southwest Oncology Group [SWOG] 9304). 1 Our hypotheses were that polymorphisms in these genes would be associated with clinical outcomes in these patients (eg, that the variant MTHFR C677T genotype would confer increased toxicity). Patients were randomly assigned to 3 different treatment arms: arm 1, with bolus 5-FU in 2 5-day cycles every 28 days before and after XRT plus 5-FU via protracted venous infusion (PVI) at a dose of 225 mg=m 2 =day during XRT; arm 2 (PVI-only arm), with PVI 42 days before and 56 days after XRT PVI; or arm 3 (bolus-only arm), with bolus 5-FU plus leucovorin (LV) in 2 5-day cycles before and after XRT, plus bolus 5-FU plus LV (levamisole was administered each cycle before and after XRT). 1 
MATERIALS AND METHODS

Study Population and Sample Collection
Patients in this study were a subset of participants recruited into the SWOG 9304 clinical trial for whom DNA was available. The detailed description of the trial has been reported previously. 1 Briefly, patients were required to have had curatively resected nonmetastatic rectal adenocarcinoma. Extension through the muscularis propria and=or lymph node spread (T3-T4N0 or T1-T4N1-N3) was required. Patients with involved radial margins were ineligible with the exception of the extraperitoneal serosal margin (T4a). Rectal cancer was defined as tumor noted intraoperatively below the peritoneal reflection or 2 cm from the anal verge. Patients with dentate involvement were eligible. Patients were required to be aged > 18 years, have a Southwest Oncology Group performance status of 0 to 2, and not be pregnant or lactating. No prior chemotherapy or XRT for rectal cancer or a prior history of rectal cancer (with the exception of previously resected T1-2N0M0 tumors) was allowed. Satisfactory pretreatment laboratory parameters and the absence of serious illness were required. Chest x-ray and abdominopelvic computed tomography scans were required within 56 days of registration. Computed tomography scans were mandatory, unless bilirubin, aspartate aminotransferase, and alkaline phosphatase were within institutional normal limits, and the surgical report specifically described the liver as normal. Registration was between days 20 to 70, and Institutional Review Board approval and written informed consent were obtained.
Patients were randomly assigned to arm 1, with bolus 5-FU administered in 2 5-day cycles every 28 days before and after XRT plus 5-FU via PVI at a dose of 225 mg=m 2 =day during XRT; arm 2 (PVI-only arm), with PVI administered 42 days before and 56 days after XRT PVI; or arm 3 (bolus-only arm), with bolus 5-FU plus LV administered in 2 5-day cycles before and after XRT, plus bolus 5-FU plus LV (levamisole was administered each cycle before and after XRT). 30 in 10-lL reactions. TaqMan polymerase chain reactions (PCRs) were run for 50 cycles on an ABI 7900HT sequence detection system (Applied Biosystems), and real-time quantitative PCR data were collected in addition to endpoint reads for allelic discrimination. The 19-base pair (bp) deletion polymorphism in intron 1 of DHFR was genotyped by size-dependent separation of fluorescently tagged PCR products as described 31 on an ABI 3130xl genetic analyzer and analyzed using GeneMapper software (Applied Biosystems). All assays were Original Article validated by genotyping 30 CEPH family trios from HapMap and comparing the results with known genotypes of these individuals, with no discrepancies or Mendelian inheritance errors. Due to the poor quality of DNA isolated from laser capture microdissected tissue, all samples were assayed at least twice for each polymorphism. Genotyping success rates ranged from 92.5% for MTHFR A1298C to 84.8% for MTHFR C677T. Approximately 5% of blinded duplicates were included in every assay and duplicate concordance rates ranged from 100% for MTHFR C677T to 95.2% for cSHMT1 C1420T, 91.5% for MTHFR A1298C, and 83.3% for DHFR del. HardyWeinberg equilibrium calculations demonstrated some divergence, largely for DHFR. Although some disequilibrium is possible in patients, there may also be some biased allele dropout. The low Hardy-Weinberg equilibrium P value for the DHFR deletion may be because of the preferential loss of the longer allele because it requires a 20% longer PCR amplicon and the DNA from formalin-fixed paraffin-embedded tissue may be degraded.
Statistical Analysis
The primary endpoints of this study were OS, DFS, and toxicity. OS was measured as the date from registration to death from any cause. Patients known to be alive were censored at the last known date of contact. DFS was defined as the time from registration to the first development of recurrent disease or of death from any cause, whichever came first. Patients still known to be alive without recurrence at the time of analysis were considered to be censored at the time of their last follow-up. OS and DFS curves were generated using the Kaplan-Meier method. Toxicities defined as per the National Cancer Institute Common Toxicity Criteria (version 2.0) were categorized by maximum grade, evaluating at grades 0 to 2 versus grades 3 to 5. The maximum grade of any toxicity was identified as well as the maximum grade of specific toxicities including hematologic, gastrointestinal, pain, and stomatitis=esophagitis.
The associations between polymorphisms and OS and DFS were analyzed using the Cox proportional hazards model (univariately and adjusted for variables used in the stratification at the time of randomization [type of surgery, lymph node involvement, primary tumor stage, and time from surgery to registration]). To obtain tests for trend, the genotypes were treated as continuous variables and we compared the likelihood ratio of a model without the variable using a chi-square test with 1 degree of freedom. The association between the polymorphisms and toxicity was tested using univariate logistic regression and logistic regression analysis adjusted for age, sex, and treatment arm. Genotypes were modeled using indicator variables for the heterozygous and the homozygous variant genotypes (unrestricted or codominant model). Given the investigations of functional candidate polymorphisms with prior hypotheses, no formal multiple comparisons adjustments were applied.
To address the joint effects of 2 functional variants, MTHFR A1298C and C677T were also a priori combined into a single variable, reflecting combined genotypes coded as 0 variants (AA and CC), 1 variant (AC=CC or AA=CT), or 2 variants (AA=TT, AC=CT, AC=TT, CC=CC, CC=CT, or CC=TT).
RESULTS
A total of 754 eligible patients were evaluated in the study, 482 of whom were men and 272 of whom were women ( Table 1 ). The patients were predominantly white (92%) and the median age was 61 years (range, 19 years-86 years). The percentage of patients randomly assigned to the 3 different treatment arms was similar. Patient characteristics included in this correlative study were similar to the remaining 1100 patients in the original study for whom specimens were not available (data not shown).
Evaluating all genotypes, including the combined genotypes in MTHFR, there were overall no statistically significant associations noted between any polymorphism and either OS or DFS (with or without adjusting for treatment assignment and=or stratification factors) ( Table 2) . Nevertheless, there was a marginal trend toward worse OS (P for trend, .08) and DFS (P for trend, .05) among variants of MTHFR C677T and better DFS (P for trend, .09) among variants of the TS 1494del. Analyses restricted to the white population yielded similar results (data not shown). Although there was no overall statistically significant trend in OS related to the DHFR 19-bp deletion polymorphism, the heterozygous genotype (wt=del) had a hazards ratio (HR) of 0.76 (95% confidence interval [95% CI], 0.59-0.99) compared with the homozygous (wt=wt) genotype.
We also explored analyses separately by treatment arm (Table 3) . These analyses revealed few differences compared with the overall analyses, with the exception that patients with the MTHFR C677T TT genotype had worse OS compared with those with homozygous wildtype at the C677T locus (HR, 1.76; 95% CI, 1.06-2.93 [P 5 .03]) and DFS (HR, 1.84; 95% CI, 1.12-3.03 [P 5 0.02]) in treatment arm 2 (PVI-only arm: PVI before and after XRT). Conversely, patients with variants of the TS 1494del genotype had better OS and DFS than those with the wild-type in treatment arm 3 (bolus-only arm: with bolus 5-FU plus LV before and after XRT). The HRs for OS comparing those with the TS 1494del-=-and 1=-genotypes were 0.61 (95% CI, 0.39-0.98; P 5 .04) and 0.65 (95% CI, 0.42-0.99; P 5 .04), respectively.
Toxicity Analysis
Because some of the toxicities, especially those that were hematologic, in the overall trial differed by treatment arm, 1 we performed stratified analyses for this endpoint (Supplementary Table) . There was a trend toward increased gastrointestinal toxicity among patients with variants of the MTHFR C677T genotype in treatment arm 1 (HRs comparing TT and CT genotypes with CC were 2.97 [95% CI, 1.13-7.86] and 1.29 [95% CI, 0.72-2.30], respectively [P for trend, .09]). There were also trends toward reduced hematological toxicity among patients with variants of SLC19A1 G80A in treatment arm 1 (HRs comparing AA and GA genotypes with GG genotype were 0.47 [95% CI, 0.22-1.00] and 0.83 [95% CI, 0.45-1.56], respectively; P for trend, .08) and reduced esophagitis=stomatitis among patients with variants of TSER in treatment arm 3 (P for trend, .06). However, no consistent patterns were observed across treatment arms.
DISCUSSION
In this randomized controlled trial, we observed no statistically significant associations between functional polymorphisms in MTHFR, DHFR, SLC19A1, SHMT1, TS 1494del, and TSER genes and clinical outcomes among patients with stage II or III rectal cancer. Nevertheless, we observed worse OS and DFS among patients with variants of MTHFR C677T and better OS and DFS among those with variants of TS 1494del compared with the wild-types in analyses stratified by treatment arm.
Although to our knowledge few studies to date have investigated the associations between MTHFR genotypes and outcomes among patients with rectal cancer, the Original Article findings of the current study are in general similar to what has been reported among patients with colorectal cancer, in whom studies, often small in size, have observed no significant associations between MTHFR genotypes and OS or DFS. 13, 14, 16, 19, 21, 23 Likewise, in a previous study among patients with rectal cancer, MTHFR genotypes were not found to be associated with OS and DFS among patients with rectal cancer, although they were associated with 5-FU toxicity. 32 Nevertheless, the findings of the current study suggest that whatever impact these variants may have on OS and DFS appear to be limited only to those patients in a particular treatment arm (treatment arm 2 for MTHFR C677T TT and treatment arm 3 for the TS 1494del genotype), which could be useful in targeted intervention. The MTHFR 677T allele has also been associated with lower response rates and worse tumor regression grade in patients with rectal cancer receiving 5-FU-based chemotherapy. 26, 31, 33 In a small study with 125 patients, the MTHFR 677T-1298A haplotype was associated with a poor response to treatment. 31 Patients with rectal cancer without the MTHFR 677T-1298A haplotype had a 71% better response rate than patients with the MTHFR 677T-1298A haplotype. 31 MTHFR is an essential regulatory enzyme in folate metabolism that diverts folate metabolites from pyrimidine synthesis toward methionine synthesis. 8 The C-to-T mutation, which occurs commonly among white individuals, 28, 34 results in a reduction in Abbreviations: 95% CI, 95% confidence interval; DHFR, dihydrofolate reductase; HR, hazards ratio; MTHFR, methylenetetrahydrofolate reductase; SWOG, Southwest Oncology Group; 0 variant, homozygous for common alleles for both polymorphisms; 1 variant, heterozygous for one of the polymorphisms; >1 variant, heterozygous for both polymorphisms or homozygous for the rare allele. a Adjusted for type of surgery, lymph node involvement, primary tumor stage, and time from surgery to registration. b P value derived from the Wald chi-square test in Cox regression analysis.
MTHFR activity, thereby leading to lower levels of 5-methyltetrahydrofolate, the accumulation of 5,10-5,10-MTHF, and elevated circulating homocysteine concentrations in patients with borderline folate status. [28] [29] [30] 34 We observed no overall statistically significant associations between TS genotypes and OS and DFS. Among patients in treatment arm 3, however, variants in the TS 1494del gene were associated with better OS and DFS compared with the wild-type, which has an allele frequency of 0.29. 35 There are conflicting reports regarding the associations between TS genotypes and clinical outcomes among patients with rectal cancer treated with Original Article 5-FU. Some studies have reported associations of TS genotypes with DFS and tumor regression whereas others have not. [36] [37] [38] [39] However, the majority of these studies had small numbers of patients and were conducted in the neoadjuvant setting.
We observed no significant associations between DHFR 19-bp deletion, SHMT1 C1420T, SLC19A1 G80A polymorphisms, and OS and DFS. The DHFR genotypes affect serum folate levels and thus could potentially mediate the effect of 5-FU treatment in patients with cancer. [40] [41] [42] Homozygosity for the 19-bp deletion polymorphism in intron 1 of DHFR is related to an increase in DHFR mRNA 43 and a decrease in plasma homocysteine. 41 Although the heterozygous genotype for the 19-bp deletion polymorphism in the DHFR gene was found to be marginally associated with OS in the current study, the homozygous genotype was not. The result needs to be interpreted with caution because the trend analysis was not statistically significant.
We observed no statistically significant associations between these genotypes and toxicity, although for some genotypes, the results of the current analyses suggest that the effect on toxicity might depend on the type of treatment. In a previous study among patients with rectal cancer, the MTHFR haplotype (677C-1298C) was shown to be protective against severe diarrhea and mucositis among patients treated with 5-FU but not among those treated with the combination of 5-FU and irinotecan. 32 Furthermore, patients with the 1298A=A genotype were reported to have a higher risk of developing grade 3 to 4 diarrhea or mucositis compared with patients with the A=C or C=C genotype 32 ; no such differences were noted in our analyses of combined MTHFR genotypes.
The therapeutic effectiveness and cytotoxicity of 5-FU is due to the impact of folate on DNA replication. 3, 4 Cancer cells as well as normal but rapidly replicating cells of the gastrointestinal and hematopoietic systems are especially susceptible to the effects of 5-FU and therefore the major sites of 5-FU toxicity are the gastrointestinal and hematopoietic cells. 4 MTHFR and TS genotypes have been reported to modify the severity of oral mucositis after hematopoietic stem cell transplantation. 44 
Strengths
The current study has several strengths. It is a large study ancillary to a completed clinical trial with a well-defined clinical database. Chemotherapy with 5-FU as well as XRT were administered according to a well-defined study protocol, and toxicities were coded according to established criteria and guidelines.
Limitations
Although the number of participants was large, because of limited DNA availability, the cohort represented only 40% of patients registered for the clinical trial. Moreover, due to differing adverse event profiles in the 3 study arms, the sample sizes to assess the associations between genotypes and adverse events required separate analyses within treatment arms, thereby limiting the power to detect associations. Due to the poor quality of DNA isolated from formalin-fixed, paraffin-embedded laser capture microdissected tissue, we were unable to obtain genotypes for all 792 of the patients for whom we had specimens, despite up to 3 attempts. We also recognize that the stratification resulted in several statistical comparisons; results therefore require further replication in comparable settings.
Conclusions
Genetic variability in folate-metabolizing enzymes was found to be associated only to a limited degree with clinical outcomes among patients with rectal cancer treated with 5-FU. Because of the interindividual variability in response to 5-FU therapy and toxicity, the identification of other genotypes that may predict therapeutic response and toxicity still remains a priority.
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